Senores Pharmaceuticals Promoter Group Creates Pledge on 4,00,000 Equity Shares

Senores Pharmaceuticals Limited has disclosed the creation of a pledge by its promoter group entity Espee Therapeutics LLP on 4,00,000 equity shares. The pledge was created under the Securities and Exchange Board of India (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, and reported to both BSE and NSE on February 17, 2026. Pledge Details The pledge creation involves specific financial and operational parameters that demonstrate the structured nature of the transaction. Parameter: Details Pledging Entity: Espee Therapeutics LLP Number of Shares Pledged: 4,00,000 Percentage of Total Share Capital: 0.87% Date of Pledge Creation: February 13, 2026 Beneficiary: Bajaj Finance Limited Purpose: Collateral for loan taken by Renosen Pharmaceuticals Private Limited Promoter Group Holdings Espee Therapeutics LLP holds a total of 4,95,000 equity shares in Senores Pharmaceuticals Limited, representing 1.0748% of the company's total share capital. The pledged shares constitute a significant portion of the entity's total holding in the company. Regulatory Compliance The disclosure was made pursuant to Regulation 31(1) and 31(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The company secretary Vinay Kumar Mishra (ICSI Membership No.: F11464) submitted the disclosure on behalf of Senores Pharmaceuticals Limited, while Swapnil Jatinbhai Shah, Designated Partner (DIN: 05259821), signed the disclosure on behalf of Espee Therapeutics LLP. Stock Exchange Listing Senores Pharmaceuticals Limited is listed on both major Indian stock exchanges with the following identifiers: BSE Scrip Code: 544319 NSE Symbol: SENORES The disclosure ensures transparency and compliance with regulatory requirements for substantial shareholding changes and encumbrance creation by promoter group entities. Senores Pharmaceuticals Limited has received a disclosure from promoter group entity Renosen Pharmaceuticals Private Limited regarding the release of pledge on 4,00,000 equity shares. The pledge was released on February 13, 2026, and disclosed to the stock exchanges on February 16, 2026, in compliance with SAST Regulations 31(1) and 31(2). Pledge Release Details The pledge release transaction involves the complete removal of encumbrance on the shares that were previously pledged as collateral to Bajaj Finance Limited: Parameter: Details Released Shares: 4,00,000 equity shares Percentage of Share Capital: 0.87% Original Pledgee: Bajaj Finance Limited Date of Pledge Release: February 13, 2026 Post-Release Encumbered Shares: 0 shares (0%) Regulatory Compliance and Documentation The disclosure was submitted to both BSE Limited (Scrip Code: 544319) and National Stock Exchange of India Limited (Symbol: SENORES) as mandated under SAST Regulations. Swapnil Jatinbhai Shah, serving as Director of Renosen Pharmaceuticals Private Limited with DIN 05259821, signed the disclosure documents on February 16, 2026. Vinay Kumar Mishra, Company Secretary and Compliance Officer (ICSI Membership No.: F11464), submitted the formal disclosure on behalf of Senores Pharmaceuticals Limited to both stock exchanges. Promoter Holdings Structure The disclosure reveals the comprehensive shareholding pattern of promoters and promoter group entities in Senores Pharmaceuticals Limited: Promoter/Entity: Shareholding Percentage Swapnil Jatin Shah: 35,53,531 shares 7.72% Ashokbhai Vijaysinh Barot: 34,44,869 shares 7.48% Remus Pharmaceuticals Limited: 32,61,744 shares 7.08% Renosen Pharmaceuticals Private Limited: 27,08,719 shares 5.88% Anar Swapnil Shah: 22,94,500 shares 4.98% Aviraj Overseas LLC: 18,95,190 shares 4.12% Company Information Renosen Pharmaceuticals Private Limited, formerly known as Senores Lifesciences Pvt. Ltd., holds a total of 27,08,719 shares in Senores Pharmaceuticals Limited, representing 5.88% of the total share capital. The company is registered with CIN U51909GJ2019PTC108258 and operates from Ahmedabad. The released pledge amount of 4,00,000 shares previously constituted encumbrance on the entity's holding, which has now been completely cleared. We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better. Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians. As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.